about-docDr. Scott Eder always strives to be at the cutting edge of medicine.  A graduate of Boston University and medical school at the Catholic University of Louvain, he also holds masters degrees in both physiology and administrative/preventative medicine. Dr. Eder is a board-certified gynecologist, recognized by the American Congress of Obstetricians and Gynecologists.

Dr. Eder opened his first office in Lawrenceville, NJ in 1988.  Since that time, he has introduced several new gynecological procedures to the Mercer County community including techniques to avoid hysterectomy and treat urinary incontinence.  Most recently, he was the first physician in Mercer County to use the DaVinci surgical robot, a device designed to make surgery less invasive.

The Center for Women’s Health and Wellness is actively involved in clinical research studies that help to bring new laboratory tests, medications and surgical treatments safely to the public. You can learn more about volunteering for these studies here.

Dr. Eder has participated in several volunteer medical missions as a gynecologist in Africa. In 2008 he was a nominee for the Distinguished Physician Humanitarian Award given by Princeton Health Care System for his work.

In 2017, Dr. Eder successfully met the criteria and passed the examination necessary to become a NAMS Certified Menopause Practitioner (NCMP).

Undergraduate

1970-1974 B.A., History
Boston University
Boston, Massachusetts

Graduate and Professional

1974-1976 M.S., Physiology
Rutgers University
New Brunswick, New Jersey
1976-1982 Doctor of Medicine
Universite Catholique de Louvain
Brussels, Belgium
1998-2000 M.S., Administrative Medicine/Preventative Health
University of Wisconsin Medical School
Madison, Wisconsin

Internship and Residency

1982-1983 Department of Internal Medicine
St. Louis University Group Hospitals
St. Louis, Missouri
1983-1987 Department of Obstetrics & Gynecology
UMDNJ-New Jersey Medical School
Newark, New Jersey
New Jersey MA43626
Missouri 36473
Pennsylvania MD-041421E
Florida ME 99513
New York 163424 (inactive)
American Board of Obstetrics & Gynecology Diplomat 1989
Recertified 1997
Recertified 2007
Voluntary Recertification,
2011, 2012, 2013, 2014, 2015, 2016, 2017
Certifying Commission in Medical Management Certified Physician Executive 2001
Association of Pharmaceutical Physicians and Investigators Certified Physician Investigator 2017
North American Menopause Society (NAMS) Certified Menopause Practitioner (NCMP) 2017
National Certification Corporation Certificate of Added Qualification in Electronic Fetal Monitoring 2012
Federal DEA AE2488460
New Jersey CDS D060991
1983-1987 Clinical Instructor II
UMDNJ-New Jersey Medical School
Newark, New Jersey
1988-1992 Clinical Instructor
UMDNJ-New Jersey Medical School
Newark, New Jersey
1992-2005
2008-present
Clinical Assistant Professor
Department of Obstetrics/Gynecology
Rutgers-New Jersey Medical School
Newark, New Jersey
2016-present Instructor (Gynecology)
Internal Medicine Residency Program
Capital Health System
Trenton, New Jersey
July 1987-December 1987 St. Mary’s Hospital
Good Samaritan Hospital
Humana Hospital
Wellington Regional Medical Center
Palms West Hospital
West Palm Beach, Florida
February 1988-present Capital Health System
Trenton, New Jersey
October 1988-2005 UMDNJ-University Hospital
Newark, New Jersey
July 1989-present University Medical Center at Princeton
Princeton, New Jersey
September 1994-2003 Robert Wood Johnson Medical Center
At Hamilton
Trenton, New Jersey
1984-1987 Clinician
Planned Parenthood of Bergen County
Hackensack, New Jersey
1988-1990 Clinician
Planned Parenthood of Mercer County
Trenton, New Jersey
1989-1991 Clinician
Rutgers Community Health Plan
Lawrenceville, New Jersey
1989-1991
1995-1996
Medical Director
Familyborn Birth Center
Princeton, New Jersey
1994-1997 Host, “Healthcare Radio Show”
New Jersey Network
Trenton, New Jersey
2006-present Physician-Medical Missions to Niger and Rwanda
International Organization for Women & Development, Inc.
Rockville Centre, New York
2011-present Medical Consultant
Exeltis
180 Park Ave.
Florham Park, New Jersey
2015-present Medical Consultant
Prima-Temp, Inc.
2820 Wilderness Place, Unit C
Boulder, CO 80027
2015-present Medical Consultant
Reckitt Benckiser LLC
One Phillips Parkway
Montvale, NJ 07645
2016-present Medical Monitor (ContraMed CMDOC-0022)
Synteract HCR, Inc.
5759 Fleet Street
Carlsbad, California 92008
1974 B.A. with distinction
1982 M.D. cum laude
1992, 1995, 1998,
2001, 2004, 2007
AMA Physician’s Recognition Award
2008 Princeton Healthcare System Nominee for 2008
Distinguished Physician Humanitarian Award
2015 Medical Society of NJ Quality Recognition Award
2016 Mercer County Medical Society 2016 Community Service Award
1992-2001 Associate Board of Governors
Capital Health System
Trenton, New Jersey
1993-present Board of Trustees
Mercer County Medical Society
Trenton, New Jersey

National and Regional

One Health Plan of NJ, Inc
One Centennial Avenue
Piscataway, NJ 08855
Southern Physician Advisory
Committee
2001-2008
Empire Blue Cross/BS
Wellchoice, Inc.
11 West 42nd Street
New York, NY 10036
Practice Guidelines Subcommittee
2000-2001
Clinical Quality Committee
2003-2007
Physician’s Healthcare Plan of NJ
Lawrenceville, New Jersey
Credentials Committee
1995-1997
Clover Health LLC
Harborside Financial Center Plaza 10
Jersey City, NJ 07211
Credentials Committee
2014-present

Hospital

Helene Fuld Medical Center
(Capital Health System)
Chairman, Medical Records
1991-1996
Continuing Medical Education
1989-1990
Credentials
1992-2000
Operations and Other Procedures
2000-2003. Chairman, 2002
Medical Center at Princeton Credentials
2000-2009

Departmental

Helene Fuld Medical Center Secretary, Ob/Gyn 1991-1992
Vice Chairman, Ob/Gyn 1994-1995
Chairman, Ob/Gyn 1995-1997
  • American College of Obstetricians & Gynecologists- Fellow
  • American College of Surgeons- Fellow
  • American Medical Association
  • New Jersey Medical Society
  • Mercer County Medical Society- President, 2004-2005
  • Association of Clinical Research Professionals

Obstetrics & Gynecology, Women’s Health

  • Rhone-Poulenc Rorer (RPR 106522-201) Principal Investigator, “A Randomized, Double-blind, Multi-Center Progestin Efficacy Study of Thee Doses of RPR Estradiol/Norethisterone Acetate (NETA) Patches in Sequential Wear HRT Regimen Compared to an Estradiol 50 Patch” 1994
  • Ortho-McNeil Pharmaceutical, Inc. (CAPSS-062) Principal Investigator, “Effect of an Extended Pill-Free Interval on Follicular Activity, Ortho Tricyclin and Alesse,” 1997-1998
  • Ortho-McNeil Pharmaceutical, Inc. (CAPSS-053) Principal Investigator, “Time to Symptomatic Relief: Terazol 3 Vaginal Cream vs. Diflucan,” 1998
  • Berlex (Protocol 96043) Principal Investigator, “A Multicenter, Double-Blind Randomized Study of Continuous Transdermal Estradiol-Levonorgesterol Combination, Compared to Continuous Transdermal Estradiol to Examine the Safety and Effects on Endometrium, Symptoms, and Bleeding Patterns in Post Menopausal Women,” 1998-1999
  • Searle (N6S-97-02-001) Principal Investigator, “Dosing Optimization with Intranasal Synarel (Naferelin Acetate) for Patients with Endometriosis,” 1999
  • Ortho-McNeil Pharmaceutical, Inc. (CAPSS-153) Principal Investigator, “A Multicenter, Randomized, Open-Label, Parallel Group Study to Evaluate the Endometrial Safety Following Treatment with Ortho-Prefest Compared to Prempro in Postmenopausal Women,” 2001
  • Ortho-McNeil Pharmaceutical, Inc. (CAPSS-320) Principal Investigator, “Comparison of the Safety and Efficacy of Patient Controlled Analgesia Delivered by Fentanyl HCl Transdermal System Versus Morphine IV Pump for Pain Management after Non-emergent Lower Abdominal or Pelvic Surgery,” 2004-2005
  • Novo Nordisk Pharmaceuticals, Inc. (VAG-2195) Principal Investigator, “A 12 month double-blind, randomized, parallel-group, placebo controlled, multicenter trial to investigate the efficacy and safety of Vagifem Low Dose (10microgram 17 beta estradiol vaginal tablet) for the treatment of postmenopausal atrophic vaginitis symptoms,” 2005
  • Duramed Research Inc. (DR-MPG-201) Principal Investigator, “A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Induction of Withdrawal Bleeding After Administration of Oral Micronized Progesterone in Women with Secondary Amenorrhea” 2005
  • Duramed Research Inc. (DR-PSE-309) Principal Investigator, “A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of an Extended Cycle, Low Dose, Combination Oral Contraceptive Regimen, DP3-Lo84/10, Which Utilizes Ethinyl Estradiol During the Seven Day Interval Between Each 84-day Cycle of Combination Therapy For the Prevention of Pregnancy in Women” 2005
  • Luitpold Pharmaceuticals, Inc. (1 VIT 03001) Principal Investigator, “Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (Vit 45) versus Oral Iron in Subjects Who Display Post Partum Anemia” 2005
  • Church & Dwight Co. Inc. (ST-6981) Principal Investigator, “Analytical Accuracy Test to Evaluate Percent Agreement Between a Male Fertility Diagnostic Device and Manual Sperm Analysis” 2006
  • Wyeth Pharmaceuticals Inc. (3115A1-304-WW) Principal Investigator, “A Double-Blind, Randomized, Placebo and Active Controlled Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogens Combinations for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women” 2006
  • Organon USA Inc. (292002) Principal Investigator, “A Randomized, Open Label, Comparative, Multi-Center Trial To Evaluate Contraceptive Efficacy, Cycle Control, Safety And Acceptability Of A Monophasic Combined Oral Contraceptive (COC) Containing 2.5 Mg Nomegestrol Acetate (NOMAC) and 1.5 Mg Estradiol (E2), Compared To A Monophasic COC Containing 3 MG Drospirenone (DRSP) and 30 Micrograms Ethinyl Estradiol (EE)” 2006
  • Church & Dwight Co. Inc. (ST-7005) Principal Investigator, “ An Observational Study to Evaluate the Safety and Ease of Self-vaginal Specimen Collection by Untrained Consumers for Intended OTC Diagnosis of Bacterial Vaginosis (BV) and Yeast Infection (YI)” 2006
  • Duramed Research Inc. (DR-CEN-302) Principal Investigator, “A Randomized, Multicenter, Double-blind, Placebo-Controlled Trial to Compare the Effects of 12 Weeks of Treatment with Cenestin Vaginal Cream vs. Placebo Vaginal Cream on Vulvovaginal Atrophy in Healthy Postmenopausal Women,” 2006
  • Xanodyne Pharmaceutical Inc. (XP12B-MR-303) Principal Investigator, “A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate Efficacy And Safety of 1.3g Oral Doses of XP12B-MR TID During Menstruation For The Treatment of Menorrhagia,” 2006
  • Symbollon Pharmaceuticals, Inc., (Protocol 005) Principal Investigator, “A Phase III, Multicenter, Randomized, Double Blind, Placebo-Controlled Study of IoGen for the Treatment of Moderate or Severe, Periodic Breast Pain Associated with Symptomatic Fibrocystic Breast Disease in Otherwise Healthy, Euthyroid, Premenopausal Women,” 2006
  • Hormos Medical Ltd. (Protocol 15-50310) Principal Investigator, “Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 mg and 60 mg Daily Doses With Placebo,” 2006
  • Medicis Pharmaceutical Corporation (MP-0104-18) Principal Investigator, “A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Minocycline Extended-Release Tablets on Spermatogenesis in Human Males,” 2007
  • Duramed Research Inc. (Protocol DR-DSG-302) Principal Investigator, “ A Prospective, Multicenter, Randomized, Double-blind Study to Evaluate Hormone Patterns and Ovarian Follicular Activity with the Oral Contraceptive Regimen DR-1021,” 2007
  • TriPath Imaging, Inc. (Protocol MP-3-01) Principal Investigator, “Intended Use Study of the SurePath Molecular Pap,” 2007
  • Xanodyne Pharmaceutical Inc. (Protocol XP12B-MR-301) Principal Investigator, “A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate Efficacy and Safety of 0.65g and 1.3g Oral Doses of XP12B-MR TID Administered During Menstruation for the Treatment of Menorrhagia,” 2007
  • Warner Chilcott (Protocol PR-05806) Principal Investigator, “An Open Label Study of the Safety and Efficacy of a New Low Dose Oral Contraceptive Containing Norethindrone Acetate and Ethinyl Estradiol,” 2007
  • Repros Therapeutics, Inc. (Protocol ZPE-201) Principal Investigator, “A Phase II, Three-Arm, Parallel Design, Dose-Ranging, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of the Selective Progesterone Receptor Modulator Proellex (CDB-4124) in the Treatment of Premenopausal Women with Symptomatic Endometriosis,” 2007
  • TriPath Imaging Inc., (Protocol TriPath 2007-2009) Principal Investigator, “Pre-Clinical Evaluation of a Panel of Biomarkers in the Differential Diagnosis of Ovarian Cancer in Patients with Abnormal Pelvic Mass,” 2008
  • FemmePharma Global Healthcare, Inc., (Protocol FP1198-001) Principal Investigator, “A Randomized , Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Evaluation of the Use of Topically Administered Danazol versus Placebo in Subjects with pain associated with Fibrocystic Breast Disease,” 2008
  • Bayer Healthcare Pharmaceuticals Inc., (Protocol 310184) Principal Investigator, “A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq (drospirenone 0.5 mg/17 beta estradiol 0.5mg, drospirenone 0.25mg/17 beta estradiol 0.3mg) for the relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks,” 2008
  • Roche Molecular Systems, Inc., (Protocol MWP-HPV-159) Principal Investigator, “Evaluation of the Amplicor HPV Test and the Linear Array High Risk HPV Genotyping Test for the Detection of High-Grade Cervical Disease in Women Undergoing Routine Cervical Cancer Screening Using Cervical Samples Prepared with the cobas x421 Instrument,” 2008
  • Graceway Pharmaceuticals LLC., (Protocol GW01-0805) Principal Investigator, “A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts,” 2008
  • KV Pharmaceutical Company, (Protocol CBC-303-603-622467) Principal Investigator, “A Randomized, Double-Blind, Parallel-Group Study to Compare the Safety and Efficacy of Clindamycin/Butoconazole Vaginal Cream with Butoconazole Alone in the Treatment of Mixed Bacterial Vaginosis/Vulvovaginal Candidiasis Infections,” 2008
  • QuatRx Pharmaceuticals Company, (Protocol 15-50821) Principal Investigator, “Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated with Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated with Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Comparing Oral Ospemifene 60mg Daily Dose With Placebo in Post Menopausal Women,” 2008
  • OraSure Technologies, Inc., (Protocol OQ-HCV-F-8) Principal Investigator, “Clinical Investigation to Evaluate the Performance of the OraQuick Rapid HCV Antibody Test,” 2008
  • Ferring Pharmaceuticals, (Protocol FPI GNRH 2008-03) Principal Investigator, “A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered from a Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment with Clomiphene Citrate or Placebo in Anovulatory or Oligoovulatory Infertile Females,” 2009
  • Bayer HealthCare Pharmaceuticals, Inc., (Protocol 91555) Principal Investigator, “Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55mg Ethinyl Estradiol and 2.1mg Gestodene in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects” 2009
  • Church and Dwight Co. Inc., (Protocol #246) Principal Investigator, “Collection of Urine Samples From Pregnant Women with Defined Prenatal Gender,” 2009
  • Church and Dwight Co. Inc., (Protocol #270) Principal Investigator, “Collection of Early Pregnancy Urine Samples,” 2009
  • Church and Dwight Co., Inc., (Protocol #279) Principal Investigator, “Collection of Urine Samples from Non-Pregnant Females of Reproductive Age Around Time of Expected Period.” 2009
  • Duramed Research, Inc., (Protocol #DR-103-301) Principal Investigator, “A Multicenter, Open-Label Study to Evaluate The Efficacy and Safety of A Combination Oral Contraceptive Regimen For The Prevention Of Pregnancy In Women,” 2009
  • Graceway Pharmaceuticals, LLC, (Protocol # GW05-0904) Principal Investigator, “ A Multicenter, Randomized, Investigator-Blinded, Phase 2, Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis,” 2010
  • Church and Dwight Co., Inc., (Protocol ST-7329) Principal Investigator, “Analytical Accuracy Test to Evaluate Percent Agreement Between a Male Fertility Diagnostic Test Device and Manuel Semen Analysis,” 2010
  • Church and Dwight Co., Inc., (Diagnostics Protocol 318) Principal Investigator, “Preliminary Evaluation of Various Optical Measurement Methodologies for Semen Analysis,” 2010
  • Boehringer-Ingelheim Pharmaceuticals, Inc., (Protocol 511.156) Principal Investigator, “A Twenty-four Week, Randomized, Double-blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin, with Up-titration, 100 Milligrams Administered Orally Once Daily in Naturally Postmenopausal Women with Hypoactive Sexual Desire Disorder in North America,” 2010
  • Warner Chilcott Company LLC, (Protocol PR-00110.0) Principal Investigator, “Effect of Udenafil on Spermatogenesis: A Double-blind, Randomized, Placebo-controlled, Parallel-group Study,” 2010
  • Church & Dwight Co. Inc, (Protocol ST-7356) Principal Investigator, “Accelerated Aging of the First Response Male Fertility Test,” 2010
  • Vermillion, Inc., (Protocol OVA2-001-C03) Principal Investigator, “Marker Discovery and Clinical Trial Testing for OVA2 using Serum From Women with a Documented Ovarian Adnexal Mass,” 2010
  • Gynuity Health Projects, Principal Investigator, “Vaginal and Rectal Clostridial Carriage Among Women of Reproductive Age In The United States,” 2011
  • Teva Branded Pharmaceutical Products R & D, Inc., (Protocol PSE-HSP-203) Principal Investigator, “A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-day Extended Cycle Oral contraceptive Regimen, Compared to Two 28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy Women,” 2011
  • Warner Chilcott (US), LLC, (Protocol PR-04409) Principal Investigator, “A Randomized, Double-Blind, Placebo-Controlled Comparison of Two Dosing Regimens of a Low Dose Estradiol Vaginal Cream With Regard to Their Safety and Efficacy in the Treatment of Symptoms of Vaginal Atrophy in Postmenopausal Women,” 2011
  • Emotional Brain New York LLC, (Protocol EB 82) Principal Investigator, “Lybrido At Home: A Double Blind, Randomized, Placebo-Controlled Dose-Finding Study to Investigate the Efficacy of Lybrido in Healthy Female Subjects with Hypoactive Sexual Desire Disorder (HSDD) and Low Sensitivity for Sexual Cues,’ 2011
  • Abbott Laboratories, (Protocol M12-663) Principal Investigator, “A Phase 2a Proof of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women with Heavy Uterine Bleeding and Uterine Fibroids,” 2011
  • Amneal Pharmaceuticals, LLC, (Protocol AM-ESD-001) Principal Investigator, “A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Estradiol Vaginal Tablet and Reference Listen Vagifem (Estradiol Vaginal Tablets) and Compare Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated with Menopause,” 2012
  • Merck Sharp & Dohme Corporation, (Protocol MK-8175A-022-019) Principal Investigator, “A Phase III, Randomized, Open-Label, Active-Control, Multicenter Trial to Study the Contraceptive Efficacy and Safety of the Commercial Batch of Oral Tablets of MK-8175A (Nomegestrol Acetate-17B-estradiol) in Health, Sexually-Active Women Aged 18-50 Years,” 2012
  • Medicis Global Services Corporation, (Protocol MMP-1601-01) Principal Investigator, “A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis,” 2012
  • Novum Pharmaceutical Research Services, (Protocol 71036006) Principal Investigator, “A Randomized, Investigator-Blind, Placebo-Controlled, Parallel Design, Multiple-Site Study Comparing Teva Pharmaceuticals Estradiol Vaginal Tablets with Vagifem (Estradiol) Vaginal Tablets (Novo Nordisk) in the Treatment of Atrophic Vaginitis,” 2012
  • AbbVie Inc., (Protocol M12-665) Principal Investigator, “A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis Associated Pain,” 2013
  • Church & Dwight Co. Inc., (Protocol 421) Principal Investigator,” Collection of Daily AM & PM Urine Samples From Ovulating Women,” 2014
  • Endoceutics, Inc., (Protocol ERC-238) Principal Investigator, “ Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause (Placebo-Controlled, Double Blind and Randomized Phase III Study,)” 2014
  • Church & Dwight Co. Inc. (Protocol ST 7485) Principal Investigator, “Clinical Evaluation of Effects of Four Personal Lubricants on Vaginal pH Among Asymptomatic Women 18 to 40 Years of Age’” 2014
  • Symbiomix Therapeutics, LLC (Protocol SYM-1219) Principal Investigator, “A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Bacterial Vaginosis,” 2014
  • Mylan Pharmaceuticals, Inc. (Protocol EVCR-11196) Principal Investigator, “Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Mylan) to Estrace Cream (0.01%; Warner Chilcott) in Postmenopausal Females with Atrophic Vaginitis,” 2014
  • Bayer HealthCare Pharmaceuticals (Protocol BAY 98-7196/15832) Principal Investigator, “A Randomized, Double Blind, Double Dummy, Parallel Group, Multi-Center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in a Vaginal Ring Versus Active Comparator and Placebo in Women with Symptomatic Endometriosis (moderate to severe pain) over a 12 Week Treatment Period,” 2014
  • Pharmacosmos A/S (Protocol P-Monofer-IDA-01) Principal Investigator, “A Phase III,
    Randomized, Open Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer) and Iron Sucrose in Subjects with Iron Deficiency Anemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly,” 2014
  • TherapeuticsMD (Protocol TXV 14-01) Principal Investigator, “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women with Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy,” 2014
  • Laboratorios Leon Farma, S. A. (Protocol CF111/303) Principal Investigator, “ A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles,” 2014
  • Palatin Technologies (Protocol BMT-301) Principal Investigator, “A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD)”2015
  • Viamet Pharmaceuticals, Inc (Protocol VT-1161) Principal Investigator, “A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients with Recurrent Vulvovaginal Candidiasis,” 2015
  • Symbiomix Therapeutics, LLC (Protocol SYM-1219) Principal Investigator, “A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-menarchal Adolescent Girls with Bacterial Vaginosis” 2015
  • Agile Therapeutics, Inc (Protocol ATI-CL23) Principal Investigator, “ A Single-arm, Open label, Multi-center Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System TCDS) 2015
  • Curatek Pharmaceuticals, LLC (Protocol MTC-001) Principal Investigator, “Solubilized Metronidazole And/or Terconazole Gels Intra-Vaginal Efficacy and Safety (SMART GIVES,”) 2016
  • Novum Pharmaceutical Research Services, Inc (Protocol 71462901) Principal Investigator “A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream USP, 0.01% (Alvogen Pine Brooke LLC) to Estrace Estradiol Vaginal Cream USP, 0.01% (Warner Chilcott) in the Treatment of Atrophic Vaginitis,” 2016
  • Lumenis (Protocol LUM-ABU-AP-16-01 VVA) Principal Investigator, The Safety and Efficacy of the FemTouch laser for the Treatment of Vulvovaginal Atrophy in Post-Menopausal Women.” 2016
  • Estetra SPRL (Protocol MIT-Es0001-C302) Principal Investigator, “ A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15mg Estetrol and 3 mg Drospirenone,” 2016
  • Pharmacosmos (Protocol P-Monofer-IDA-03) Principal Investigator, “A phase III, randomized, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer) and iron sucrose in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion,” 2016
  • Lumenis (Protocol LUM-ABU-AP-17-01 VVA) Principal Investigator, “The Long-Term Safety and Efficacy of the FemTouch for the Treatment of Vulvovaginal Atrophy in Post-Menopausal Women” 2017
  • BocaBiolistis (Protocol DVM-00059) Principal Investigator, “Prospective Collection of Specimens for the Development of the Aptima Vaginosis Assays” 2017

Instructor (gynecology), Capital Health System Internal Medicine Residency Program.

Instruction to residents and medical students in obstetrics and gynecology and family practice. Volunteer faculty, Clinical Assistant Professor, Department of Obstetrics, Gynecology and Women’s Health, New Jersey Medical School

Lecturer and trainer to physician audiences for major pharmaceutical companies including Organon, Warner Chilcot, Ortho-McNeil, Lilly, Merck, Rhone-Poulenc-Rorer, and Shionogi.

Producer and Host, “Healthcare Radio Show,” New Jersey Network, New Jersey’s state sponsored public broadcasting station, offering the public a weekly half hour call in, drive time healthcare show highlighting the latest developments in medicine.

Inpatient and outpatient care, Capital Health System and Medical Center at Princeton

Principal Investigator, Women’s Health Research Center, L.L.C.

1986-1987 Chief Resident
Department of Ob/Gyn
UMDNJ-New Jersey Medical School
Newark, New Jersey
1991-2009 Founder and C.E.O.
Delaware Valley Ob/Gyn and Infertility Group, P.C.
Lawrenceville, New Jersey
1995-1997 Chairman
Department of Obstetrics & Gynecology
Helene Fuld Medical Center
Trenton, New Jersey
1998-present Owner
Women’s Health Research Center/The Center for Women’s Health & Wellness, L.L.C.
Plainsboro, New Jersey
2004-2005 President
Mercer County Medical Society
Ewing, New Jersey
July 1987-December 1987 1897 Palm Beach Lakes Blvd.
West Palm Beach, Florida
February 1988-Sept. 2009 2 Princess Road, Suite C
Lawrenceville, New Jersey
September 2009-present 666 Plainsboro Road
Plainsboro, New Jersey3100 Princeton Pike Bldg. 1
Lawrenceville, New Jersey
  1. Eder S., Chatterjee M., Salvio C.: “Evaluation of Meteneprost Potassium (A PGE2 Analogue) for Cervical Dilation and Side Effects in Non-Pregnant Women,” Prostaglandin 32:19 (1986)
  2. Eder S., Apuzzio J., Weiss, G.: “ Varicella Pneumonia During Pregnancy: Treatment of Two Cases with Acyclovir,” American Journal of Perinatology 5:16 (1988)
  3. Lippman, Joel, Creinin, Mitchell D., Eder, Scott E., Mellon, Richard W., Godwin, Amy, and Olson, William,: “The Effect of Extending the Pill-Free Interval on Follicular Activity: Triphasic Norgestimate/35 microgram ethinyl estradiol (EE) versus Monophasic Levonorgestral/20 microgram,” Contraception 66:147-152 (2002)
  4. Lukes, Andrea S., Moore, Keith A., Muse, Ken N., Gersten, Janet K., Hecht, Bryan R., Edlund, Mans, Richter, Holly E., Eder, Scott E., Attia, George R., Patrick, Donald L., Rubin, Arkady, and Shangold, Gary A.: “Tranexamic Acid Treatment for Heavy Menstrual Bleeding,” Obstetrics & Gynecology 116:865-875 (2010)
  5. Lee, Stephen R., Kardos, Keith W., Schiff, Eugene, Berne, Cheryl A., Mounzer, Karam, Banks, Alpha T., Tatum, Harvey A., Friel, Timothy J., DeMicco, Michael P., Lee, William M., Eder, Scott E., Monto, Alexander, Yearwood, Graham D., Guillon, Geraldine B., Kurtz, Lisa A., Fischl, Mark, Unangst, Jay Lynn, Kriebel, Feiss, Gary. Roehler, Michele: “Evaluation of a New, Rapid Test for Detecting HCV Infection, Suitable for Use With Blood or Oral Fluid,” Journal of Virological Methods 172: 27-31 (2011)
  6. Lukes, AS, Baker, J., Eder, S., Adomako, TL,: “Daily Menstrual Blood Loss and Quality of Life in women with Heavy Menstrual Bleeding,” Women’s Health (Lond Engl.) 8 (5):503-11 (2012)
  7. Portman, DJ, Bachmann GA, Simon JA; Ospemifene Study Group: “Ospemifene, a Novel Selective Estrogen Receptor Modulator for Treating Dyspareunia Associated with Postmenopausal Vulvar and Vaginal Atrophy,” Menopause, 2013 June; 20 (6): 623-30
  8. Eder, S., Baker, J., Gersten J., Mabey RG, Adomako TL.: “Efficacy and Safety of Oral Tranexamic Acid in Women with Heavy Menstrual Bleeding and Fibroids,” Women’s Health (Lond Engl.) 2013 Jul; 9 (4): 397-403
  9. Eder, SE “Evaluation of the EmbaGYN Pelvic Floor Muscle Stimulator in Addition to Kegel Exercises for the Treatment of Female Stress Urinary Incontinence: a Prospective, Open-Label, Multicenter, Single-Arm Study,” Women’s Health (Lond, Engl.)2014 Jan; 10 (1):17-27
  10. Eder, SE, “Ospemifene: A Novel Selective Estrogen Receptor Modulator for Treatment of Dyspareunia,” Women’s Health ( Lond.Engl.) 2014 Sept;10(5):499-503
  11. Chavoustie SE, Eder SE, Koltun WD, Lemont TR, Mitchell C, Nyirjesy P, Sobel JD, Sobel R, Villanueva R, “Experts Explore the State of Bacterial Vaginosis and the Unmet Needs Facing Women and Providers,” Int J Gynaecol Obstet.
    2017 Mar 6. Doi: 10.1002/ijgo.12114 (Epub ahead of print)
  12. Chen Y, Bruning E, Rubino J, Eder SE, “Role of Female Intimate Hygiene in Vulvovaginal Health: Global Hygiene Practices and Product Usage,”
    Women’s Health (Lond). 2017 Sept 1: 1745505717731011.doi:
    10.1177/1745505717731011 (Epub ahead of Print)

Eder S, Chatterjee M., Salvio C.: “Evaluation of a PGE2 Analogue for Pre-operative Cervical Dilation” in Proceedings of the XI World Congress of Gynecology and Obstetrics in Gynecology and Obstetrics, Edited by H. Ludwig and K. Thomsen, Springer-Verlag, New York (1986)

Lukes, Andrea, Hecht, Bryan, Eder, Scott, Attia, George, Shangold, Gary, Moore, Keith,: “Reduced Impact of Heavy Menstrual Bleeding on Physical and Social Activity of Women Using XP12B-MR,” Papers on Current Clinical and Basic Investigation, American College of Obstetrics & Gynecology Annual Clinical Meeting, May 4, 2009, San Francisco

Lukes, A., Waldbaum, A., Eder, S., Moore, K., Shangold, G., “Novel Tranexamic Acid (TA) Product (XP12B-MR) For Heavy Menstrual Bleeding: Dose-Response Analysis.” Abstract for Poster Presented at American College of Obstetricians and Gynecologists Annual Meeting, San Francisco May 15-19, 2010

Eder, Scott, Hecht, Bryan, Attia, George, Trott, Ed, “Improvement in the Frequency of Sleep Interruptions for Women with Heavy Menstrual Bleeding Treated with Tranexamic Acid” Abstract for Poster Presented at National Medical Association Meeting, July 23, 2011, Washington, DC

Eder, Scott, “Responder Analysis and Durability of Tranexamic Acid Treatment Response in Heavy Menstrual Bleeding,” Abstract Presented at National Medical Association Meeting, July 24, 2011, Washington, DC

Eder, Scott, “New Uses for CO2 Laser,” Talk Presented at New Zealand Society of Cosmetic Medicine, August 13, 2016, Queenstown, New Zealand

Eder, Scott E. “Improvement in the Genitourinary Syndrome of Menopause Following Fractional CO2 Laser Treatment in Post-Menopausal Women,” Poster Presentation, North American Menopause Society 2017 Annual Meeting,
Philadelphia October 11-14, 2017

(Revised October 30, 2017)